DOI QR코드

DOI QR Code

Novel Mutations in the CPT1A Gene Identified in the Patient Presenting Jaundice as the First Manifestation of Carnitine Palmitoyltransferase 1A Deficiency

  • Choi, Jong Sub (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Yoo, Hyeoh Won (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Lee, Kyung Jae (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ko, Jung Min (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Moon, Jin Soo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ko, Jae Sung (Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2015.08.03
  • Accepted : 2015.10.04
  • Published : 2016.03.30

Abstract

Carnitine palmitoyltransferase 1A (CPT1A) is an enzyme functioning in mitochondrial fatty acid oxidation (FAO) of the liver. Patients with CPT1A deficiency have impaired mitochondrial FAO and display hypoketotic hypoglycemia and hepatic encephalopathy as typical manifestations. In this report, we present a case of CPT1A deficiency presenting jaundice as the first manifestation. A 1.9 years old boy showed jaundice and elevated levels of free and total carnitine were observed. From direct sequencing analysis of CPT1A, two novel mutations, c.1163+1G>A and c.1393G>A (p.Gly465Arg), were identified. At the age of 2.2 years, hypoglycemia, tachycardia, and altered mental status developed just after cranioplasty for craniosynostosis. High glucose infusion rate was required for recovery of his vital signs and mentality. Diet rich in high carbohydrate, low fat and inclusion of medium chain triglyceride oil resulted in improvement in cholestatic hepatitis and since then the boy has shown normal growth velocity and developmental milestones to date.

Keywords

References

  1. Collins SA, Sinclair G, McIntosh S, Bamforth F, Thompson R, Sobol I, et al. Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut. Mol Genet Metab 2010;101:200-4. https://doi.org/10.1016/j.ymgme.2010.07.013
  2. Bennett MJ, Santani AB. Carnitine palmitoyltransferase 1A deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, eds. GeneReviews(R). Seattle, WA: Seattle University of Washington, 1993.
  3. Lee BH, Kim YM, Kim JH, Kim GH, Kim JM, Kim JH, et al. Atypical manifestation of carnitine palmitoyltransferase 1A deficiency: hepatosplenomegaly and nephromegaly. J Pediatr Gastroenterol Nutr 2015;60: e19-22. https://doi.org/10.1097/MPG.0b013e3182a95a42
  4. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004;25:495-520. https://doi.org/10.1016/j.mam.2004.06.004
  5. Morris AA, Olpin SE, Bennett MJ, Santani A, Stahlschmidt J, McClean P. Cholestatic jaundice associated with carnitine palmitoyltransferase IA deficiency. JIMD Rep 2013;7:27-9.
  6. Greenberg CR, Dilling LA, Thompson GR, Seargeant LE, Haworth JC, Phillips S, et al. The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populations. Mol Genet Metab 2009;96:201-7. https://doi.org/10.1016/j.ymgme.2008.12.018
  7. Fingerhut R, Roschinger W, Muntau AC, Dame T, Kreischer J, Arnecke R, et al. Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem 2001;47: 1763-8.
  8. Tsuburaya R, Sakamoto O, Arai N, Kobayashi H, Hasegawa Y, Yamaguchi S, et al. Molecular analysis of a presymptomatic case of carnitine palmitoyl transferase I (CPT I) deficiency detected by tandem mass spectrometry newborn screening in Japan. Brain Dev 2010;32: 409-11. https://doi.org/10.1016/j.braindev.2009.03.004
  9. Prasad C, Johnson JP, Bonnefont JP, Dilling LA, Innes AM, Haworth JC, et al. Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNAbased newborn screening program. Mol Genet Metab 2001;73:55-63. https://doi.org/10.1006/mgme.2001.3149
  10. Brown NF, Mullur RS, Subramanian I, Esser V, Bennett MJ, Saudubray JM, et al. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res 2001;42: 1134-42.
  11. Bennett MJ, Boriack RL, Narayan S, Rutledge SL, Raff ML. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab 2004;82:59-63. https://doi.org/10.1016/j.ymgme.2004.02.004
  12. Falik-Borenstein ZC, Jordan SC, Saudubray JM, Brivet M, Demaugre F, Edmond J, et al. Brief report: renal tubular acidosis in carnitine palmitoyltransferase type 1 deficiency. N Engl J Med 1992;327:24-7. https://doi.org/10.1056/NEJM199207023270105

Cited by

  1. Mitochondrial pyruvate and fatty acid flux modulate MICU1-dependent control of MCU activity vol.13, pp.628, 2016, https://doi.org/10.1126/scisignal.aaz6206
  2. Cpt1a promoted ROS-induced oxidative stress and inflammation in liver injury via the Nrf2/HO-1 and NLRP3 inflammasome signaling pathway vol.99, pp.5, 2016, https://doi.org/10.1139/cjpp-2020-0165